On August 28, 2026 Mabqi reported it will participate in the Ion Channel-Targeted Drug Development Summit, taking place September 23–24 at Hotel Commonwealth in Boston, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Johanna Marines, Head of Preclinical Development at Mabqi, is invited to give an oral presentation on : Targeting TRPV6 with Bispecific Antibodies to Enable Selective Ion Channel Modulation for Anti-Tumor Activity in Oncology

The presentation will highlight TRPV6 as a promising oncology target, the mechanism of action of a TRPV6-targeting bispecific antibody, and preclinical in vitro and in vivo efficacy data supporting further clinical development.

The summit brings together leaders from biopharma and academia to advance selective and safe ion channel therapeutics through new approaches in electrophysiology, structural biology and translational science.

(Press release, Mabqi, AUG 28, 2026, View Source [SID1234670412])